When clinicians have to make hard decisions, IQ2™ and ZOE™ trade; provide hard data.
The ability to monitor, evaluate and optimize cardiac performance, pulmonary status and tissue perfusion early in a patient’s treatment, creates the opportunity to optimize therapeutic decision making.
IQ2™ noninvasive hemodynamic monitoring:
- Delivers objective assessment of the heart’s mechanical performance.
- Provides continuous data to optimize fluid management.
- Enables precise and rapid titration of diuretics and inotropes.
Identifies impending onset of shock.
- Optimizes confident goal-directed therapeutic decision making.